Health Economics for Prescribers

Slides:



Advertisements
Similar presentations
McGraw-Hill/Irwin © 2006 The McGraw-Hill Companies, Inc., All Rights Reserved. 1.
Advertisements

Health Economics for Prescribers
Health Economics for Prescribers
Health Economics for Prescribers
Health Economics for Prescribers
Economic Evaluation Ken Stein Public Health Physician North & East Devon Health Authority University of Exeter.
Economics 302 Lecture 2 Topics Topics Aggregate Output (Standard Measure) GDP vs GPI discussion The Other Major Macroeconomic Variables (Unemployment and.
Payment by Results: Setting the Tariff Liz Eccles Deputy Director of Policy and Strategy Department of Health.
OPERATIONS MANAGEMENT INTEGRATING MANUFACTURING AND SERVICES FIFTH EDITION Mark M. Davis Janelle Heineke Copyright ©2005, The McGraw-Hill Companies, Inc.
Correcting Market Distortions: Shadow Prices, Shadow Wages and Discount Rates Chapter 6.
Chapter 7 The Cost of Production. Chapter 7Slide 2 Topics to be Discussed Measuring Cost: Which Costs Matter? Cost in the Short Run Cost in the Long Run.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
COST-BENEFIT ANALYSIS Chapter 8. Projecting Present Dollars into the Future R=$ T=years r=interest rate How much will $1000 earn in 2 years at an interest.
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Measuring the State of the Economy
Introduction to Health Economics
Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.
F O U R T H E D I T I O N Financial Analysis in Operations Management © The McGraw-Hill Companies, Inc., 2003 supplement 5 DAVIS AQUILANO CHASE PowerPoint.
Chapter 11: Cost-Benefit Analysis Econ 330: Public Finance Dr
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Drug and Therapeutics Committee
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Chapter 6 Cost of Production.
Dr Rakesh Kumar Moderator- Dr PR Deshmukh
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
CTC 475 Review  Course Requirements  Applications  Multiple Decision Criteria  Selling The Project  PSP.
1 EGGC4214 Systems Engineering & Economy Lecture 2 Cost Concepts and Economic Environment.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
1 OECD Handbook on Measuring Volume Output of Education and Health Chapter 3: Health Sandra Hopkins OECD Health Division June 2007.
Study Unit 9 Decision Analysis and Risk Management.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 4: Measuring costs - Part 1 Sept 15,
COST BENEFIT ANALYSIS- PUBLIC SECTOR INVESTMENTS Lucky Yona.
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
Business Funding & Financial Awareness CAPITAL BUDETING J R Davies May 2011.
Review of the previous lecture Oligopolists maximize their total profits by forming a cartel and acting like a monopolist. If oligopolists make decisions.
National Institute of Economic and Social Research Metrics, Targets and Performance: Hospital Star Ratings Mary O’Mahony, Philip Stevens and Lucy Stokes.
Making Costing Fun. But, how much does it cost? Session Objectives: –Introduce costing as a tool for decision making (advocacy and design). –Empower participants.
1 ECGD4214 Systems Engineering & Economy. 2 Lecture 1 Part 1 Introduction to Engineering Economics.
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 6: Cost-effectiveness analysis – Part.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Principles of Macroeconomics Lecture 1 INTRODUCTION TO MACROECONOMICS & MEASURING ECONOMIC ACTIVITY.
Study Unit 9 Decision Analysis and Risk Management.
Promoting high quality, cost effective drug therapy throughout the Military Health System Identification and Use of Published Health Economic Evaluations.
Calculating Costs, Revenues and Profit. Today’s session  Identification of fundamental business cost elements  Distinguishing between revenue and profit.
1 Cost-Benefit Analysis Public Economics Minda DC. Eduarte.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Study Unit 7 The cost of production. Outcomes Different concepts of costs in economics Cost in the short run Cost in the long run Short run cost vs. long.
CRJS 4466 PROGRAM & POLICY EVALUATION LECTURE #6 Evaluation projects Questions?
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Cost Analysis Dr Rakesh Kumar Moderator- Dr PR Deshmukh.
Chapter McGraw-Hill/Irwin Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Short-Run Alternative Choice Decisions 26.
Programme Initaitive overview / Background information
Lecture 15 Assoc. Prof. Sencer Ecer HEALTH ECONOMICS
Feasibility.
“Analytical Tools and Data Collection” Workshop April 2009 EuropeAid/125317/D/SER/TR Roman Ladus Session 6 Measuring Impacts 1.
EWG Study Tour, Galway, 18/09/2006
Health Economics M.MHLANGA 1.
Sergio Bautista-Arredondo National Institute of Public Health Mexico
Assessing value for money: principles, methods and issues
Health Economics for Prescribers
Health Economics for Prescribers
Health Economics for Prescribers
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Health Economics for Prescribers Richard Smith (MED) richard.smith@uea.ac.uk David Wright (CAP) d.j.wright@uea.ac.uk 1

Workshop reminder Read paper and checklist prior to workshop Group X = Cote et al. A pharmacy-based health promotion programme in hypertension. Pharmacoecon, 2003; 21: 415-428. Group Y = Scuffham & Chaplin. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. Pharmacoecon, 2004; 22: 525-535. Workshop 1 – checklist items 1, 2, 3 and 4-6 (re: costs) Workshop 2 – checklist items 4-6 (re: benefits) and 7,8,9,10 Read paper and checklist prior to workshop 93

Lecture 2 recap The ‘why and what’ of economic evaluation How it relates to other forms of evaluation Types of economic evaluation – CMA, CEA, CUA, CBA 93

Types of economic evaluation Type of Analysis Result Consequences Costs Cost Minimisation Cost Benefit Cost Utility Cost Effectiveness Money Single or multiple effects not necessarily common. Valued as “utility” eg. QALY Different magnitude of a common measure eg., LY’s gained, blood pressure reduction. Least cost alternative. Identical in all respects. Cost per unit of consequence eg. cost per LY gained. Cost per unit of consequence eg. cost per QALY. As for CUA but valued in money. Net £ cost: benefit ratio. 93

Lecture 2 recap The ‘why and what’ of economic evaluation How it relates to other forms of evaluation Types of economic evaluation – CMA, CEA, CUA, CBA Stages in an economic evaluation 93

Stages in economic evaluation Deciding upon study question Viewpoint taken. Alternatives appraised. Assessment of costs and benefits Identification of relevant C&B. Measurement of C&B. Valuation of C (&B). Adjustment for timing. Making a decision. Adjustment for uncertainty. 93

Lecture 2 recap The ‘why and what’ of economic evaluation How it relates to other forms of evaluation Types of economic evaluation – CMA, CEA, CUA, CBA Stages in an economic evaluation ‘Drummond’ checklist for appraisal Items 1, 2 and 3 of checklist 93

‘Drummond’ checklist Was a well-defined question posed in answerable form? Was a comprehensive description of alternatives given? Was there evidence that effectiveness had been established? Were all the important and relevant costs and consequences for each alternative identified? Were costs and consequences measured accurately/appropriately? Were costs and consequences valued credibly? Were costs and consequences adjusted for differential timing? Was an incremental analysis performed? Was allowance made for uncertainty? Did presentation/discussion of results include all issues of concern? 93

Lecture 3: Pharmaco-economic evaluation – resources and costs Identification (checklist 4) Indirect costs Measurement (checklist 5) Fixed, variable and total cost Average, marginal and incremental cost (checklist 8) Discounting (checklist 7) Valuation (checklist 6) Cost versus price Inflation Sources of unit cost data 93

Resource use measurement and costing: overview of process Identification: Viewpoint/perspective. Resources with an opportunity cost. Measurement: Measure in natural physical units (eg. hours of labour time). Valuation: Market prices (eg. wage rates) used unless strong belief they do not reflect opportunity cost (eg volunteers). Calculation: Multiply unit of measurement by unit cost (eg 2 hours of time at £5 per hour = £10 labour cost). 93

1. Identification Which to include depends on perspective taken Intervention Direct Cost Indirect Costs Wider cost implications to society eg. lost production. Non-health services resource use. Eg. patient transportation, informal care Health services resource use. Eg. Inpatient, outpatient, tests, drugs Costs to family and friends. Which to include depends on perspective taken 93

‘Indirect’ cost Human capital approach (Rice and Cooper, 1967) Gross wage as value of working and leisure time Friction cost approach (Koopmanschap et al, 1992/3/5) Labour markets usually exhibit involuntary unemployment Value of productivity changes therefore accrue during short period of adjustment – the ‘friction period’ Example: 1996 costs of premature mortality in Canada $105 million using human capital method $1.53 million using friction cost method Criticisms of either method Introduce bias as both based no wage rate (non-earners?) Double counting if QALYs are outcome measure 93

2. Measurement of resource use Need to quantify resource use in appropriate physical and natural units hours, days, miles, dose etc Direct costs are mostly assessed, and categorised as: Capital costs (buildings, equipment) Overheads (jointly used resources, such as heating and lighting, administration and catering) Labour (medical and non-medical staff) Consumables (disposable items, such as drugs, bandages etc) 93

Fixed, variable and total cost Fixed cost (FC) costs that in the short run do not vary with quantity, usually capital, overheads (labour?) Variable cost (VC) costs which vary with the level of service, usually consumables (labour?) Total cost (TC) all costs incurred while producing a service = FC + VC 93

Fixed, variable and total cost TC Cost VC FC Quantity 93

Average versus marginal cost Average cost cost per unit of output Influenced by fixed cost Marginal cost cost of producing an extra unit Influenced by variable cost 93

Average and marginal cost curves MC AC The marginal private cost (MPC) of producing a good is the increase in total private cost from producing an additional unit. The marginal private cost curve is the industry supply curve under perfect competition. Quantity 14

Importance of marginal cost 93

Importance of marginal cost cont… 93

Marginal versus incremental cost TC of Prog A Cost MCA, Q* TC of Prog B ICA-B, Q* Q* MCB, Q* Quantity 93

Discounting Prefer to have benefits now and bear costs in the future – ‘time preference’ ‘Rate’ of time preference is termed ‘discount rate’ To allow for differential timing of costs (and benefits) between programmes all future costs (and benefits) should be stated in terms of their present value using discount rate Thus, future costs given less weight than present costs 93

Discounting example 93

Which discount rate? 5%: used by US studies in the 70’s and 80’s, such that convention emerged 3.5%: UK government recommended and used in other areas of public sector In general, whatever rate used undertake sensitivity analysis (range often 2%-10%) 93

Specific use of discounting: capital costs Capital costs represent an investment in an asset which is used over time Purchased at the beginning of the programme and then depreciates over time Two components opportunity cost of initial investment depreciation over time In a evaluation, annualise the initial capital outlay over the useful life of the asset calculate the equivalent annual cost E.g. If cost £1,200 (K), life expectancy 9 years (n), discount rate 6% (r) then E = £176 93

3. Valuation Resources should be valued according to their opportunity cost In most markets price is a good reflection of opportunity cost but health care provision is rarely subject to market valuations Use of prices predominates but should be justified, and alternative ‘shadow’ prices may need to be used 93

Price ≠ cost Price = Cost only in a (perfectly) competitive market Health care markets are rarely competitive pharmaceuticals subject to bilateral monopolies and discounts labour markets are imperfect cross subsidisation inefficiencies in production Q P=C S (MC) D (MB) 93

Types of costing Valuation is dependent on the form of measurement Costing can be performed “top down” or “bottom up” Average per diem, daily cost per patient Disease-specific per diem, average daily cost for treatments within disease areas Case-mix group, cost for each category (e.g. DRGs or HRGs) Micro-costing, cost of each component of resource use Choice between these is often dependent on data availability and time constraints 93

Sources of unit cost data Published sources Government (NHS reference costs) previous research provider accounts BNF (British National Formulary) Direct valuation (eg patient out-of-pocket expenses – travel, time, OTC, child care) Questionnaires Diaries 93

NHS ‘reference costs’ (prices) Payment by Results (implementation of the national tariff from April 2005) Based on hospital returns, within specific HRGs Results in published unit costs which are “consistent” day cases, elective and emergency procedures 500 surgical procedures, almost 5 million episodes across 249 NHS Trusts Limitations excludes atypical episodes costing methods are not standard inconsistent definitions 93

Adjustments Unit cost data may need to be adjusted for Price inflation (costs from different years) International currencies (costs from different countries) 93

Adjusting for price inflation Hospital and Community Health Services (HCHS) pay and price index weighted average of Pay Cost Index (PCI) and Health Service Cost Index (HSCI) If we know the cost of a hip replacement in 2002/03 was £5,000 but we want it in 1998-99 prices: 93

HCHS versus general inflation 93

Adjusting for international currencies Purchasing Power Parities (PPPs) and exchange rates are two methods that are used to convert different currencies into a common denominator PPPs are more appropriate than exchange rates as these eliminate the difference in price levels between countries PPPs are calculated from a common basket of goods 93

Summary Any evaluation must distinguish between identification, measurement and valuation of resource use Identification perspective is important range of costs justified by perspective Measurement need to distinguish between fixed, variable and total cost, and average, marginal costs and incremental cost may need to adjust for differential timing (discounting) Valuation method of valuation needs justification (incl. market prices) price does not necessarily equate with cost precision – ‘top down’ versus ‘bottom up’ may need to adjust for inflation or currencies 93